RxDoctor Payments Data

Jeffrey Sparks, MD

Internal Medicine · Burlington, NCNPI 1811958168

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Pfizer. That places this record below the midpoint for internal medicine clinicians in NC, where the typical reported total is $163.

$18in general payments, 2019–2025

Across 1 payment — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$18
$604,534in research payments, 2019–2025

Across 88 payments — averaging $6869.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$551K
  • Kowa Research Institute, Inc.$54K
  • Boehringer Ingelheim$35

What the payments were for

  • Food & beverage$18100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$18

How this compares

$18 in reported general payments places this provider in the 20th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$186,480
Medicare patients
290
Services billed
6,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$220,631
MounjaroTirzepatide57$97,804
OzempicSemaglutide77$89,133
JardianceEmpagliflozin79$69,755
XareltoRivaroxaban30$48,593
RybelsusSemaglutide20$41,713
JanuviaSitagliptin Phosphate37$40,933
MyrbetriqMirabegron48$36,237
JanumetSitagliptin Phos/Metformin Hcl16$22,586
TrulicityDulaglutide15$22,120
LinzessLinaclotide40$22,064
RexultiBrexpiprazole11$20,673
WegovySemaglutide13$17,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,605
Lagevrio (Eua)Molnupiravir30$13,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$220,631220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →